European Patent Organisation

Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)

Retrieved on: 
Thursday, May 6, 2021
Intellectual property law, European Patent Organisation, Patent law, European Patent Office, Patent application, Patent, Outline of patents, Patent prosecution

The decision of the Mexican patent authority follows the European Patent Office (EPO) "Intention to Grant a European Patent"notice to the company from October 2020, concerning the same patent application.\nEyal Barad, Cannabics Pharmaceuticals\' co-founder and CEO commented: "This patent application is a great example of Cannabics\'s innovative and novel approach to the drug discovery process in our field.

Key Points: 
  • The decision of the Mexican patent authority follows the European Patent Office (EPO) "Intention to Grant a European Patent"notice to the company from October 2020, concerning the same patent application.\nEyal Barad, Cannabics Pharmaceuticals\' co-founder and CEO commented: "This patent application is a great example of Cannabics\'s innovative and novel approach to the drug discovery process in our field.
  • The patent was already granted in Israel and in South Africa, and we have been notified of intention to grant in Europe and now also in Mexico.
  • This opens many interesting opportunities for the company in these markets, which we intend to develop and grow.
  • We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time.

Securing Smartphones Through an Integrated Biometric Authentication Solution: Bo Pi and Yi He named European Inventor Award 2021 Finalists

Retrieved on: 
Tuesday, May 4, 2021
Biometrics, Identification, Fingerprint, Human anatomy, European Patent Organisation, Invention, Capacitive sensing, European Inventor Award, Human–computer interaction, Human behavior, Branches of biology

Their invention shows how innovation can help protect our privacy and security," says EPO President Antnio Campinos, announcing the European Inventor Award 2021 finalists.

Key Points: 
  • Their invention shows how innovation can help protect our privacy and security," says EPO President Antnio Campinos, announcing the European Inventor Award 2021 finalists.
  • "For the inventors, protecting their intellectual property with patents helped facilitate cooperation, attract licensing partners and helped their technology gain a foothold in multiple markets.
  • Although inspired by the release of the first fingerprint scanning technology, the duo quickly saw that these early scanners could be fooled by spoof attacks.
  • It simultaneously activates a conventional capacitive sensor that traces a map of where a fingerprint\'s conductive ridges hit the conductive plate.

InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe

Retrieved on: 
Wednesday, April 7, 2021
Intellectual property law, Patent law, European Patent Organisation, Monopoly, Patent, Novelty, European Patent Office

STOCKHOLM, April 7, 2021 /PRNewswire/ --InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company's DIMS platform has been granted by the European Patent Office.

Key Points: 
  • STOCKHOLM, April 7, 2021 /PRNewswire/ --InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company's DIMS platform has been granted by the European Patent Office.
  • InDex has a preclinical portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents.
  • The new European patent, entitled Biologically active oligonucleotides capable of modulating the immune system (patent number 3165607), covers both the composition-of-matter and method-of-use of 19 different DIMS compounds for the treatment of inflammatory diseases, cancer and infectious diseases.
  • "This patent has previously been granted in the US and Canada, and we are very pleased that also the European Patent Office confirms the novelty of our DIMS platform."

InDex Pharmaceuticals gets patent for additional DIMS compounds granted in Europe

Retrieved on: 
Wednesday, April 7, 2021
Intellectual property law, Patent law, European Patent Organisation, Monopoly, Patent, Novelty, European Patent Office

STOCKHOLM, April 7, 2021 /PRNewswire/ --InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company's DIMS platform has been granted by the European Patent Office.

Key Points: 
  • STOCKHOLM, April 7, 2021 /PRNewswire/ --InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company's DIMS platform has been granted by the European Patent Office.
  • InDex has a preclinical portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents.
  • The new European patent, entitled Biologically active oligonucleotides capable of modulating the immune system (patent number 3165607), covers both the composition-of-matter and method-of-use of 19 different DIMS compounds for the treatment of inflammatory diseases, cancer and infectious diseases.
  • "This patent has previously been granted in the US and Canada, and we are very pleased that also the European Patent Office confirms the novelty of our DIMS platform."

GBT - 3D Chip and Memory Patent Enters the Regional Phase in Europe

Retrieved on: 
Wednesday, March 17, 2021
Countries, Foreign relations, Government, European Patent Organisation, Patent Cooperation Treaty, European Patent Convention, European Patent Office, Patent

The application has been allocated the number 19862631.9 and designates all EPC states (as of the PCT filing date).

Key Points: 
  • The application has been allocated the number 19862631.9 and designates all EPC states (as of the PCT filing date).
  • It is expected that the European Patent Office will shortly issue a communication under Rule 161 EPC.
  • This will invite GBT to file a response to the WO (ISA)/IPRP as well as the opportunity to reduce the claims to avoid fees at that stage.
  • GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents.

European Patent Office Report Shows U.S. Patent Applications Fell by 4% During Pandemic

Retrieved on: 
Tuesday, March 16, 2021
Countries, Intellectual property law, Law, European Patent Organisation, European Patent Office, European Patent Convention, Patent application

The overall number of European patent applications across all countries filed in 2020 remained stable, decreasing by 0.7% compared with the previous year.

Key Points: 
  • The overall number of European patent applications across all countries filed in 2020 remained stable, decreasing by 0.7% compared with the previous year.
  • The EPO received 180,250 patent applications in total, which was slightly below the record level attained in 2019 (181,532).
  • The U.S. nonetheless remained the largest country of origin for European patent applications in 2020, accounting for almost a quarter of the total.
  • Peter Gorman, Shepard Fox Communications (USA), +1 617-669-4329, [email protected]
    Luis Berenguer Gimnez / Rainer Osterwalder, European Patent Office (EPO), +49 89 2399 1820, [email protected]

PyroGenesis Announces European Patent Office’s Intent to Grant Plasma Atomization (3D Printing) Patent; Increasing Productivity and Further Controlling Particle Size Distribution

Retrieved on: 
Thursday, March 11, 2021
Countries, Government, Law, European Patent Organisation, Patent offices, Monopoly, Patent, European Patent Convention, Outline of patents

Specifically, this patent aims at providing a simplified device geared to increasing productivity while at the same time allowing for further control over particle size distribution, thereby reducing overall costs.

Key Points: 
  • Specifically, this patent aims at providing a simplified device geared to increasing productivity while at the same time allowing for further control over particle size distribution, thereby reducing overall costs.
  • This patent has been filed for patent protection in an additional six different jurisdictions.
  • European patents provide protection not only in the 38 member states of the European Patent Organization, but also in two extension states plus four validation states.
  • This represents an area with approximately 700 million inhabitants1, said Pierre Carabin, Chief Technology Officer of PyroGenesis.

Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury

Retrieved on: 
Wednesday, March 10, 2021
Intellectual property law, Patent offices, Patent law, International Searching and Preliminary Examining Authorities, European Patent Organisation, Intellectual property organizations, European Patent Office, United States Patent and Trademark Office, Patent office, Patent

"This new patent further strengthens our intellectual property focused on the treatment of neurodegenerative diseases," commented Maria Maccecchini, Ph.D., CEO of Annovis.

Key Points: 
  • "This new patent further strengthens our intellectual property focused on the treatment of neurodegenerative diseases," commented Maria Maccecchini, Ph.D., CEO of Annovis.
  • "We believe there are additional opportunities to expand our patent coverage both globally and in the US.
  • The Company received its first PD patent (US 10,383,851) from the USPTO in August 2019 and its first AD patent (EP 2683242) from the European Patent Office (EPO) in March 2020.
  • The EPO approved Annovis Bio's first acute patent (EP 3334425B1) in December 2020.

Ellomay Capital Ltd. Announces Execution of EPC Agreement in connection with a Project to Construct a 28MW Photovoltaic Plant in Spain

Retrieved on: 
Tuesday, March 9, 2021
Metka, EPC, European Patent Organisation, Companies, Industry economics), Contract law

The EPC Agreement provides a fixed and lump-sum amount of 15.32 million for the complete execution and performance of the works defined in the EPC Agreement.

Key Points: 
  • The EPC Agreement provides a fixed and lump-sum amount of 15.32 million for the complete execution and performance of the works defined in the EPC Agreement.
  • The EPC Agreement includes additional standard provisions, including with respect to liquidated damages in connection with delays and performance, performance guarantees, suspension and termination.
  • METKA EGN Spain is expected to complete the works under the EPC Agreement within a period of 9 months from receipt of the Notice to Proceed.
  • The Company continues to develop a large number of additional photovoltaic projects in Spain, Italy, and Israel.

Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy

Retrieved on: 
Thursday, March 4, 2021
Intellectual property law, Countries, Law, European Patent Organisation, Patent law, Business law, Monopoly, Patent, European Patent Office, Inventor, European Patent Convention, Outline of patents

The patent is titled, "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs.

Key Points: 
  • The patent is titled, "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs.
  • The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc., which is the exclusive, world-wide licensee.
  • Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, "We are pleased that the European Patent Office (EPO) has issued this patent.
  • This patent will provide protection of our technology throughout the European Union, in addition to the existing protection from our issued patent in the United States.